Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) is looking for acquisitions. The Company reported that it has closed its underwritten public offering of shares of its common stock. The Company sold 10,000,000 shares of its common stock in the offering at a public offering price of $15.00 per share.

The net proceeds from the sale of the shares, after underwriting discounts and estimated expenses, was approximately $140.1 million. The Company plans to use the net proceeds from the offering (i) to fund the potential acquisition of new product candidates, and (ii) for general corporate purposes.